Compounds > 1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine
Page last updated: 2024-12-09

1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you're asking about, **1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine**, is a **chemical compound**, not a naturally occurring substance. It is not found in nature, and its importance is primarily related to its potential **biological activity** and **pharmacological applications**, which are still under investigation.

Here's what we know about it:

* **Structure:** It consists of a benzimidazole ring with a sulfonamide group attached at the 1 position and an amino group at the 2 position. The 4-chlorophenyl group is attached to the sulfonamide.

* **Potential Applications:** This compound is being studied as a potential **lead molecule for drug development**. Its structure suggests that it could interact with biological targets related to various disease areas, including:
* **Cancer:** Benzimidazole derivatives are known to exhibit anti-tumor activity.
* **Infectious diseases:** Compounds containing sulfonamide groups can have antimicrobial properties.
* **Neurological disorders:** Benzimidazole derivatives have been investigated for their potential effects on the nervous system.

* **Research Importance:** The importance of 1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine lies in its potential to be a starting point for the development of new therapeutic agents. Researchers are interested in:
* **Synthesizing and characterizing:** Understanding the chemical properties of the compound.
* **Evaluating its biological activity:** Testing it against different disease targets and assessing its efficacy and safety.
* **Optimizing its structure:** Modifying the compound to enhance its properties and potentially improve its therapeutic potential.

**Important Note:** The research on 1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine is still in its early stages. It is crucial to emphasize that this compound is not yet approved for any therapeutic use, and its potential benefits and risks are still under investigation.

Cross-References

ID SourceID
PubMed CID1088439
CHEMBL ID1521474
CHEBI ID92152

Synonyms (22)

Synonym
IDI1_003333
CHEMDIV2_004618
BAS 07162071 ,
MLS-0425609.0001 ,
MLS-0425609.0002
MLS002639480
smr001548924
HMS1382B20
AKOS000641832
1-(4-chlorophenyl)sulfonylbenzimidazol-2-amine
CHEMBL1521474
cid_1088439
[1-(4-chlorophenyl)sulfonylbenzimidazol-2-yl]amine
bdbm62170
us9328112, b36
1-(4-chlorophenyl)sulfonyl-2-benzimidazolamine
CHEBI:92152
1-(4-chlorobenzenesulfonyl)-1h-benzimidazol-2-amine
Q27163934
DTXSID101220593
1-[(4-chlorophenyl)sulfonyl]-1h-benzimidazol-2-amine
799264-48-5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency16.46870.000811.382244.6684AID686978; AID686979
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency112.20203.548119.542744.6684AID743266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
interleukin-8 isoform 1 precursorHomo sapiens (human)IC50 (µMol)3.82000.55074.397718.7700AID2245; AID2250; AID2260
tumor necrosis factorHomo sapiens (human)IC50 (µMol)20.00000.07935.809814.7275AID2337
nucleotide-binding oligomerization domain-containing protein 1 isoform 1Homo sapiens (human)IC50 (µMol)10.33120.04313.361918.4900AID2255; AID2261; AID2264; AID2333
nucleotide-binding oligomerization domain-containing protein 2 isoform 1Homo sapiens (human)IC50 (µMol)19.70001.14607.137219.7000AID2334
Aldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)IC50 (µMol)1.20001.20003.43505.6700AID1068474
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)IC50 (µMol)19.90000.03704.33077.9433AID1178167; AID655844
Nucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)IC50 (µMol)0.09000.09000.96912.7000AID1178166; AID655843
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
cellular aldehyde metabolic processAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
lipid metabolic processAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
xenobiotic metabolic processAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
positive regulation of interleukin-10 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of JNK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
temperature homeostasisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
pattern recognition receptor signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
innate immune response in mucosaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
adaptive immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of dendritic cell antigen processing and presentationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of T cell mediated immunityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of dendritic cell cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-positive bacteriaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of type 2 immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
phagocytosisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
defense responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteriaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
JNK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to nutrientNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of biotic stimulusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of bacteriumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
maintenance of gastrointestinal epitheliumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of appetiteNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of type II interferon productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-12 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-18 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-2 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-12 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-17 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-6 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-8 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
toll-like receptor 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to endoplasmic reticulum stressNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
intracellular signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
intestinal stem cell homeostasisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
defense response to bacteriumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to exogenous dsRNANucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
innate immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of Notch signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of gamma-delta T cell activationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
host-mediated regulation of intestinal microbiota compositionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of epithelial cell proliferationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of inflammatory responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of phagocytosisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of B cell activationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
establishment of localization in cellNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to lipopolysaccharideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to peptidoglycanNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to organic cyclic compoundNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of neutrophil chemotaxisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
xenophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
antibacterial innate immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of mitophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of xenophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of macrophage apoptotic processNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
pattern recognition receptor signaling pathwayNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of dendritic cell antigen processing and presentationNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense responseNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
inflammatory responseNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
JNK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
detection of biotic stimulusNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
detection of bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of interleukin-1 beta productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of interleukin-6 productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of interleukin-8 productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
response to endoplasmic reticulum stressNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
intracellular signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense response to bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
innate immune responseNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of JNK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense response to Gram-negative bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
defense response to Gram-positive bacteriumNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
nucleotide-binding oligomerization domain containing 1 signaling pathwayNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cellular response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
xenophagyNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
positive regulation of xenophagyNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (22)

Processvia Protein(s)Taxonomy
aldehyde dehydrogenase (NAD+) activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
aldehyde dehydrogenase [NAD(P)+] activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
protein bindingAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
alcohol dehydrogenase (NADP+) activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
benzaldehyde dehydrogenase (NAD+) activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
3-chloroallyl aldehyde dehydrogenase activityAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
actin bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ATP bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
enzyme bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein kinase bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Hsp70 protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
muramyl dipeptide bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
pattern recognition receptor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
peptidoglycan bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ubiquitin bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ADP bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein-containing complex bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
CARD domain bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Hsp90 protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
ATP bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
pattern recognition receptor activityNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
identical protein bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
protein homodimerization activityNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
peptidoglycan bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
ubiquitin bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
protein-containing complex bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
CARD domain bindingNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
extracellular spaceAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
endoplasmic reticulumAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
cytosolAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
plasma membraneAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
cytoplasmAldehyde dehydrogenase, dimeric NADP-preferring Homo sapiens (human)
cytosolNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
extrinsic component of plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytoplasmNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
mitochondrionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Golgi apparatusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytosolNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytoskeletonNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cell surfaceNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
basolateral plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
vesicleNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
phagocytic vesicleNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein-containing complexNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cytoplasmNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
cytosolNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
basolateral plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
apical plasma membraneNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
phagocytic vesicleNucleotide-binding oligomerization domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1448716Inhibition of NOD1 in human PBMC-derived macrophages assessed as reduction in C12-iE-DAP-stimulated IL6 mRNA expression at 1 uM preincubated for 1 hr followed by C12-iE-DAP stimulation for 90 mins by RT-qPCR analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.
AID655845Inhibition of TNFalpha-induced NFkappaB activation in HEK293T cells after 14 hrs by luciferase reporter gene assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
AID655846Cytotoxicity against HEK293T cells at 20 uM by alamar blue assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
AID655843Inhibition of NOD-1 mediated NFkappaB activation in HEK293T cells assessed as inhibition of gamma-tri-DAP-induced luciferase activity after 14 hrs by reporter gene assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
AID1068462Inhibition of human ALDH1A3 using propionaldehyde as substrate up to 100 uM preincubated for 1 min followed by substrate addition by spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.
AID1068474Inhibition of human ALDH3A1-mediated benzaldehyde oxidation preincubated for 1 min followed by substrate addition by spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.
AID1178166Inhibition of NOD1 (unknown origin) expressed in HEK293T cells coexpressing NF-kappaB driven luciferase reporter gene by HTS primary assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway.
AID1178167Inhibition of NOD2 (unknown origin) expressed in HEK293T cells coexpressing NF-kappaB driven luciferase reporter gene by HTS primary assay2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway.
AID1068463Inhibition of human ALDH1A2 using propionaldehyde as substrate up to 100 uM preincubated for 1 min followed by substrate addition by spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.
AID1068464Activation of human ALDH1A1 using propionaldehyde as substrate at 100 uM preincubated for 1 min followed by substrate addition by spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.
AID1068465Inhibition of human ALDH2 using propionaldehyde as substrate preincubated for 1 min followed by substrate addition by spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.
AID655844Inhibition of NOD-2 mediated NFkappaB activation in HEK293T cells assessed as inhibition of MDP-induced luciferase activity after 14 hrs by reporter gene assay2011ACS medicinal chemistry letters, Oct-13, Volume: 2, Issue:10
Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation.
AID1178168Selectivity ratio of IC50 for NOD2 (unknown origin) to IC50 for NOD1 (unknown origin)2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway.
AID1068461Inhibition of human ALDH1B1 using propionaldehyde as substrate up to 100 uM preincubated for 1 min followed by substrate addition by spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.
AID1448717Inhibition of NOD1 in human PBMC-derived macrophages assessed as reduction in C12-iE-DAP-stimulated TNFalpha mRNA expression at 1 uM preincubated for 1 hr followed by C12-iE-DAP stimulation for 90 mins by RT-qPCR analysis2017Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12
Discovery of 1,4-Benzodiazepine-2,5-dione (BZD) Derivatives as Dual Nucleotide Binding Oligomerization Domain Containing 1/2 (NOD1/NOD2) Antagonists Sensitizing Paclitaxel (PTX) To Suppress Lewis Lung Carcinoma (LLC) Growth in Vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's6 (75.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.39 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.1510taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
3-methyl-7-pentyl-8-(2-phenylethylthio)purine-2,6-dione
[no description available]		3.1910oxopurine
3-methyl-7-(phenylmethyl)-8-(propan-2-ylthio)purine-2,6-dione
[no description available]		3.1910oxopurine
1-(4-methylphenyl)sulfonyl-2-benzimidazolamine
[no description available]		3.5820sulfonamide
1-(benzenesulfonyl)-2-benzimidazolamine
[no description available]		2.0610sulfonamide
1-(4-nitrophenyl)sulfonyl-2-benzimidazolamine
[no description available]		2.0610sulfonamide
1-(4-methoxyphenyl)sulfonyl-2-benzimidazolamine
[no description available]		2.0610sulfonamide
5,6-dimethyl-1-(4-methylphenyl)sulfonyl-2-benzimidazolamine
[no description available]		2.0610sulfonamide
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Asthma, Bronchial
[description not available]		03.0110
Colitis, Granulomatous
[description not available]		03.0110
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		03.0110
Crohn Disease
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.		03.0110
Carcinoma, Lewis Lung
A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.		02.1510